693 - DoxyPEP: A “Morning-After Pill” for STIs

<p data-pm-slice="1 1 []">An alarming rise in sexually transmitted infections like chlamydia, gonnorhea, and syphilis in the US calls for new prevention and treatment tactics. <strong>Dr. Matthew Hamill</strong>, a Johns Hopkins clinical researcher specializing in HIV and STIs, talks with <strong>Stephanie Desmon</strong> about DoxyPEP, or the use of antibiotic doxycycline after sexual contact. They discuss its effectiveness and availability, use in the context of antibiotic resistance, and why DoxyPEP isn’t a silver bullet in the prevention of STIs.</p>